Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS-ND)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03402919|
Recruitment Status : Recruiting
First Posted : January 18, 2018
Last Update Posted : October 4, 2019
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||2300 participants|
|Official Title:||The Comprehensive Assessment of Neurodegeneration and Dementia Study|
|Actual Study Start Date :||June 2016|
|Estimated Primary Completion Date :||September 2023|
|Estimated Study Completion Date :||September 2023|
Normal healthy elderly
participants with no subjective or objective cognitive deficits or decline.
Subjective Cognitive Decline
Participants with a complaint of subjective cognitive impairment, but no objective evidence of such.
Mild Cognitive Impairment (MCI)
Participants with objective evidence of cognitive impairment, but it does not impact on daily function.
Participants meeting criteria of MCI who also show signs of cerebrovascular disease on imaging but have no history of stroke.
Participants with dementia of the Alzheimer's type according to the National Institute of Aging-Alzheimer's Association criteria
Dementia of Mixed Etiology
Participants with dementia and evidence of more than one etiology.
Lewy Body/Parkinson's spectrum
Participants with Parkinson's disease who show mild or moderate cognitive impairment and/or dementia.
Frontotemporal dementia (FTD) spectrum
Participants with behavioral variant FTD, primary progressive aphasia, progressive supranuclear palsy, or corticobasal syndrome
- Montreal Cognitive Assessment (MoCA) score [ Time Frame: 2 years ]change in MoCA total score. The MoCA is a test of global cognition scored out of 30 with a higher score indicating better performance. The minimum score is 0 and the maximum score is 30.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03402919
|Contact: Howard Chertkow, MD||514 340 8222 ext email@example.com|
|Contact: Victor Whitehead, MSW||514 340 8222 ext firstname.lastname@example.org|
|Study Director:||Michael Borrie, MD||Western University|